WPSS MDS Score Calculator
Select WHO MDS category, karyotype, and transfusion dependency to calculate the WPSS score and estimate risk group with median overall survival.
For educational use only. WPSS estimates are based on population-level data from the original derivation cohort. All results must be interpreted by a qualified hematologist or oncologist in the full clinical context. Not a substitute for clinical judgment.
1 WHO MDS Category
Select the WHO-defined sub-type based on bone marrow and peripheral blood findings.
2 Cytogenetic Risk Group (Karyotype)
Based on bone marrow cytogenetic analysis.
3 Transfusion Dependency
Red blood cell transfusion requirement assessed over a 4-month period.
Select all three variables on the left
and click Calculate.
WPSS Score
Score Components
Clinical Notes
WPSS Score — Risk Group Reference
| Score | Risk Group | Median OS | ~5-yr AML Risk |
|---|---|---|---|
| 0 | Very Low | 136 months (~11.3 yrs) | ~3% |
| 1 | Low | 63 months (~5.3 yrs) | ~8% |
| 2 | Intermediate | 44 months (~3.7 yrs) | ~20% |
| 3–4 | High | 19 months (~1.6 yrs) | ~45% |
| 5–6 | Very High | 8 months (~0.7 yrs) | ~70% |
Source: Malcovati L et al., J Clin Oncol 2007. Median OS and AML risk estimates reflect the original derivation cohort and may differ in contemporary practice.
Summary
Select WHO MDS category, karyotype, and transfusion dependency to calculate the WPSS score and estimate risk group with median overall survival.
How it works
- Select the WHO MDS sub-type that best fits the patient's bone marrow and blood findings.
- Choose the cytogenetic risk group based on the karyotype from the bone marrow cytogenetic analysis.
- Indicate whether the patient is transfusion dependent (requires at least 1 red cell unit every 8 weeks over a 4-month period).
- Click Calculate to compute the total WPSS score (0–6).
- Review the resulting risk group, estimated median overall survival, and 5-year AML evolution risk.
Use cases
- Estimate prognosis at diagnosis or during follow-up in MDS patients.
- Guide treatment decisions: watchful waiting vs. disease-modifying therapy vs. stem cell transplant.
- Risk-stratify patients for clinical trial eligibility.
- Counsel patients and families on expected disease course.
- Serial assessment over time to detect disease progression.
- Educate hematology trainees on MDS prognostic variables.